Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05113342 · ClinicalTrials.gov registry record · Phase 1
Descartes-25 in Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Cartesian Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05113342 is a Phase 1 study that was terminated before completion, run by Cartesian Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT05113342, a Phase 1 study, was terminated before completion, sponsored by Cartesian Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.
Interventions
- DRUG Descartes-25
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-11-25 |
| Est. Completion | 2024-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05113342
The ClinicalTrials.gov registry entry for NCT05113342 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cartesian Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Descartes-25 is the first listed.
NCT05113342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05113342 about?
NCT05113342 is a clinical study titled "Descartes-25 in Relapsed/Refractory Multiple Myeloma". This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.
What is the current status of trial NCT05113342?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-11-25. Estimated completion is 2024-11-08.
What interventions are being tested in trial NCT05113342?
The interventions under investigation include: Descartes-25 (DRUG).
Who is sponsoring clinical trial NCT05113342?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.